GO:0070100 negative regulation of chemokine-mediated signaling pathway: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0070100 describes any process that decreases the rate, frequency or extent of a chemokine-mediated signaling pathway, a critical brake on leukocyte recruitment and inflammation [1,3].
• Negative regulation can occur through receptor desensitization, decoy receptors, biased allosteric modulation, and heterologous down-modulation of chemokine receptors [2,7].
• Key molecular players include CCR2, CXCR3, CXCR4, ACKR2/D6, GRK2/3, beta-arrestins, and TLR2-dependent pathways [2,3,7].
• Dysregulation of this process contributes to chronic inflammatory diseases, cancer metastasis, and impaired immune responses in aging [6,8].
• Experimental models for studying this term include knockout mice, point-mutant chemokine receptors, and CRISPR knock-in reporters [3,8].
• EDITGENE provides CRISPR knockout, point mutation, knock-in, overexpression, and library screening services to dissect negative regulation of chemokine signaling.
Description
The Gene Ontology term GO:0070100, negative regulation of chemokine-mediated signaling pathway, defines any process that decreases the rate, frequency or extent of a chemokine-mediated signaling pathway [1,3]. Chemokine-mediated signaling is essential for directed cell migration of leukocytes, hematopoietic stem cells, and vascular cells during development and immunity [1,4,5]. However, unchecked chemokine signaling can lead to excessive tissue infiltration by neutrophils and monocytes, contributing to inflammatory tissue damage [1,7]. Therefore, negative regulation of this pathway is crucial for resolving inflammation and maintaining immune homeostasis [3,7]. Researchers study this term to understand how endogenous inhibitors, receptor desensitization, and decoy receptors control chemokine gradients and cell trafficking [2,3,7]. This article synthesizes current knowledge on the mechanisms, key genes, and experimental models for investigating negative regulation of chemokine-mediated signaling, based on published literature and the QuickGO definition.
negative regulation of chemokine-mediated signaling pathway At A Glance
| GO ID | GO:0070100 |
|---|---|
| GO term | negative regulation of chemokine-mediated signaling pathway |
| Ontology | biological_process |
| Synonym | negative regulation of chemokine-mediated signalling pathway |
| Definition | Any process that decreases the rate, frequency or extent of a chemokine-mediated signaling pathway. |
| Major function | Dampening chemokine signaling to control leukocyte trafficking, inflammation resolution, and tissue homeostasis. |
| Related processes | Chemotaxis, inflammatory response, G protein-coupled receptor desensitization, receptor internalization. |
| Key regulators | ACKR2/D6, GRK2/3, beta-arrestins, TLR2, CCR2, CXCR3, CXCR4. |
| Disease relevance | Chronic inflammation, cancer metastasis, autoimmune diseases, immunosenescence. |
What Is GO:0070100?
According to QuickGO, GO:0070100 is a biological process defined as any process that decreases the rate, frequency or extent of a chemokine-mediated signaling pathway. In other words, it encompasses all molecular events that dampen or shut down the intracellular signaling cascade triggered when chemokines bind to their receptors. This negative regulation can occur at multiple levels, including ligand sequestration, receptor desensitization, internalization, degradation, or inhibition of downstream effectors [2,3,7].
Why Is negative regulation of chemokine-mediated signaling pathway Important in Cell Biology?
Negative regulation of chemokine-mediated signaling is essential for preventing excessive and prolonged inflammation, which underlies many chronic diseases [1,3]. It also plays a role in cancer by modulating tumor cell migration and metastasis. Understanding this process can reveal therapeutic targets for inflammatory disorders and cancer, and it is critical for interpreting immune responses in aging and vaccination.
• Controls neutrophil and monocyte infiltration into tissues, preventing collateral damage.
• Regulates hematopoietic stem cell trafficking and bone marrow retention.
• Modulates vascular smooth muscle cell recruitment during artery development.
• Influences chronic lymphocytic leukemia cell migration and arrest.
• Affects immune responses in elderly individuals after vaccination.
• Provides targets for anti-inflammatory drug development [2,3].
• Helps explain biased signaling at chemokine receptors.
• Contributes to heterologous desensitization of chemokine receptors by TLR2 ligands.
• Plays a role in resolution of inflammation and tissue repair.
• Can be exploited to enhance cancer immunotherapy by modulating tumor microenvironment.
What Happens During negative regulation of chemokine-mediated signaling pathway?
Receptor desensitization by GRKs and beta-arrestins
In simple terms: After a chemokine binds its receptor, the receptor is quickly phosphorylated and uncoupled from G proteins, stopping the signal.
G protein-coupled receptor kinases (GRKs) phosphorylate activated chemokine receptors, promoting binding of beta-arrestins. This leads to desensitization and internalization, effectively terminating signaling [2,7]. For example, CXCR3 can be negatively modulated by allosteric modulators that bias signaling and reduce chemotaxis.
Decoy and scavenging receptors
In simple terms: Some receptors bind chemokines but do not signal, acting as sinks that remove chemokines from the environment.
Atypical chemokine receptors such as ACKR2/D6 bind inflammatory CC chemokines and target them for degradation without activating G proteins, thereby reducing chemokine availability and dampening signaling. This is a key mechanism of negative regulation in inflamed tissues.
Heterologous down-modulation by TLRs
In simple terms: Activation of other receptors, like TLR2, can reduce the surface levels of chemokine receptors, making cells less responsive to chemokines.
TLR2-dependent pathways can down-modulate CCR1, CCR2, and CCR5 on human blood monocytes, leading to reduced chemokine-mediated migration. This crosstalk represents an important negative regulatory mechanism during infection and inflammation.
Intracellular negative feedback loops
In simple terms: Inside the cell, signaling intermediates can be inhibited by phosphatases or other negative regulators.
Pertussis toxin-sensitive G alpha i proteins mediate chemokine signaling, and their regulation can be negatively controlled by RGS proteins and other feedback inhibitors. Additionally, ZAP70 expression can modulate integrin valency and affect chemokine-driven migration in leukemia cells, illustrating downstream negative regulation.
Ligand sequestration and degradation
In simple terms: Chemokines can be captured and destroyed by enzymes or decoy molecules, reducing the amount available to trigger signaling.
Chemokine regulation involves proteolytic processing and binding to glycosaminoglycans or decoy receptors, which can limit their signaling capacity [1,3]. This extracellular negative regulation is crucial for shaping chemokine gradients during inflammation resolution.
Key Genes Involved in GO:0070100 negative regulation of chemokine-mediated signaling pathway
The following genes and proteins are central to the negative regulation of chemokine-mediated signaling, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ACKR2 (D6) | Decoy receptor for inflammatory CC chemokines | Controls inflammation resolution; knockout models show enhanced chemokine signaling |
| GRK2 | Phosphorylates activated chemokine receptors | Desensitization of CXCR4, CCR2, etc. |
| GRK3 | Phosphorylates activated chemokine receptors | Desensitization of CXCR4, CCR2, etc. |
| ARRB1 (beta-arrestin 1) | Scaffold protein that uncouples receptors from G proteins | Mediates internalization and desensitization |
| ARRB2 (beta-arrestin 2) | Scaffold protein that uncouples receptors from G proteins | Mediates internalization and desensitization |
| CXCR3 | Chemokine receptor for CXCL9/10/11 | Negative allosteric modulators bias signaling |
| CCR2 | Receptor for CCL2/MCP-1 | Regulatory role in inflammation; down-modulated by TLR2 [3,7] |
| CCR1 | Receptor for multiple CC chemokines | Down-modulated by TLR2 in monocytes |
| CCR5 | Receptor for CCL3/4/5 | Down-modulated by TLR2 in monocytes |
| CXCR4 | Receptor for CXCL12 | Regulated by GRKs and arrestins |
| TLR2 | Pattern recognition receptor | Induces heterologous down-modulation of chemokine receptors |
| ZAP70 | Tyrosine kinase | Enhances chemokine-driven migration in CLL; potential negative regulator via integrin valency |
| GNAI1 (G alpha i1) | G protein subunit | Mediates chemokine signaling; pertussis toxin-sensitive |
| GNAI2 (G alpha i2) | G protein subunit | Mediates chemokine signaling; pertussis toxin-sensitive |
| GNAI3 (G alpha i3) | G protein subunit | Mediates chemokine signaling; pertussis toxin-sensitive |
| RGS1 | Regulator of G protein signaling | Negative regulator of chemokine signaling (inferred from general G protein regulation) |
| RGS2 | Regulator of G protein signaling | Negative regulator of chemokine signaling (inferred) |
How Is negative regulation of chemokine-mediated signaling pathway Regulated?
The negative regulation of chemokine-mediated signaling is itself tightly regulated. GRK-mediated phosphorylation and beta-arrestin recruitment are the primary mechanisms for short-term desensitization. Long-term regulation involves receptor internalization and degradation, as well as transcriptional changes in receptor expression. Heterologous regulation by TLR2 can down-modulate multiple chemokine receptors, integrating inflammatory signals. Additionally, decoy receptors like ACKR2 are upregulated by inflammatory cytokines to scavenge chemokines and resolve inflammation. These layers of regulation ensure that chemokine signaling is transient and spatially confined.
negative regulation of chemokine-mediated signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ACKR2 | Inflammation resolution | Knockout mouse, overexpression in cell lines |
| CCR2 | Atherosclerosis, multiple sclerosis | Point mutant knock-in mice [3,7] |
| CXCR3 | Autoimmune diseases, cancer | Allosteric modulator treatment in cell models |
| ZAP70 | Chronic lymphocytic leukemia | Knockout or knockdown in CLL cell lines |
| TLR2 | Sepsis, inflammatory diseases | Knockout mice, monocyte cell lines |
Chronic Inflammatory Diseases
Impaired negative regulation of chemokine signaling leads to excessive leukocyte infiltration and tissue damage in diseases such as rheumatoid arthritis, atherosclerosis, and inflammatory bowel disease [1,3]. For example, deficiency in ACKR2/D6 results in exacerbated inflammation in mouse models.
Cancer Metastasis
Chemokine signaling promotes tumor cell migration and metastasis. Negative regulators such as GRKs and arrestins can suppress metastatic spread by desensitizing chemokine receptors. In chronic lymphocytic leukemia, ZAP70 expression enhances chemokine-driven migration, suggesting that targeting this pathway could reduce leukemia cell trafficking.
Immunosenescence and Vaccination
In elderly individuals, altered chemokine signaling and negative regulation may contribute to impaired immune responses after vaccination. Understanding these mechanisms could improve vaccine strategies for older adults.
Vascular Development
Chemokine-mediated signaling within arteries promotes vascular smooth muscle cell recruitment, and its negative regulation is necessary for proper vessel wall formation. Dysregulation may contribute to vascular pathologies.
From negative regulation of chemokine-mediated signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X negatively regulate chemokine signaling? | CRISPR knockout in chemokine-responsive cell lines (e.g., HEK293, THP-1) |
| How does a point mutation in a chemokine receptor affect desensitization? | CRISPR point mutation knock-in in primary monocytes or cell lines |
| Can a decoy receptor be overexpressed to reduce inflammation? | Overexpression of ACKR2 in mouse models or cell lines |
| What is the role of GRK2 in receptor internalization? | Knockout or knockdown of GRK2 followed by chemotaxis assays |
| How does TLR2 crosstalk down-modulate CCR2? | TLR2 knockout mice and monocyte migration assays |
| Does ZAP70 modulate integrin valency in CLL? | ZAP70 knockout in CLL cell lines and adhesion assays |
How to Study the negative regulation of chemokine-mediated signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Transwell migration | Cell migration toward chemokine | Assess negative regulation of chemotaxis |
| Calcium flux | Intracellular calcium release | Measure chemokine receptor activation |
| cAMP assay | Inhibition of adenylyl cyclase | Measure Gi-coupled signaling |
| Flow cytometry | Surface receptor expression | Quantify receptor internalization |
| Western blot | Receptor phosphorylation | Detect GRK-mediated desensitization |
| CRISPR screen | Gene knockout effects on signaling | Identify novel negative regulators |
| RNA-seq | Transcriptional changes | Profile chemokine receptor expression |
| Proteomics | Protein interactions and modifications | Map signaling complexes |
Chemotaxis and Migration Assays
Transwell or microfluidic chemotaxis assays measure the ability of cells to migrate toward chemokine gradients. These are used to assess the functional impact of negative regulators on chemokine signaling [1,8].
Receptor Internalization and Desensitization Assays
Flow cytometry or immunofluorescence can quantify surface receptor levels after chemokine stimulation. Phosphorylation of receptors can be detected by Western blotting to assess GRK-mediated desensitization [2,7].
Calcium Flux and cAMP Assays
Chemokine receptor activation triggers calcium release and inhibits cAMP. These second messenger assays are used to measure signaling strength and the effect of negative regulators.
CRISPR Screens and Transcriptomics
Genome-wide CRISPR knockout screens can identify genes that negatively regulate chemokine signaling. RNA-seq and single-cell transcriptomics reveal expression changes in chemokine receptors and regulators.
How CRISPR Can Be Used to Study GO:0070100 negative regulation of chemokine-mediated signaling pathway
Knockout
CRISPR knockout of candidate negative regulators (e.g., ACKR2, GRK2) in chemokine-responsive cells can reveal their role in dampening signaling. For example, knocking out ACKR2 in macrophages leads to enhanced chemokine accumulation and inflammation.
Point Mutation
Introducing point mutations in chemokine receptors (e.g., phosphorylation sites) using CRISPR base editing or HDR can dissect the molecular determinants of desensitization and negative regulation [2,7].
Knock-in
Knock-in of tagged chemokine receptors (e.g., GFP or HA) allows real-time tracking of receptor trafficking and internalization, providing insights into negative regulation mechanisms.
Overexpression
Overexpressing decoy receptors or negative regulators (e.g., ACKR2, beta-arrestin) in cell lines or mouse models can suppress chemokine signaling and reduce inflammation, validating their therapeutic potential.
How EDITGENE Supports negative regulation of chemokine-mediated signaling pathway Research
Researchers studying negative regulation of chemokine-mediated signaling pathway-related genes often need to determine whether a candidate gene is causally involved in dampening chemokine responses. EDITGENE provides a comprehensive suite of CRISPR services to enable such investigations, from gene knockout to precise point mutations and library screens.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of chemokine-mediated signaling pathway research.
Frequently Asked Questions About negative regulation of chemokine-mediated signaling pathway
What is GO:0070100?
GO:0070100 is a Gene Ontology term for negative regulation of chemokine-mediated signaling pathway, describing any process that decreases the rate, frequency or extent of chemokine signaling [1,3].
What genes are involved in negative regulation of chemokine-mediated signaling pathway?
Key genes include ACKR2, GRK2, GRK3, ARRB1, ARRB2, CCR2, CXCR3, TLR2, and ZAP70 [2,3,7,8].
How does negative regulation of chemokine signaling occur?
It occurs via receptor desensitization by GRKs and arrestins, decoy receptors like ACKR2, heterologous down-modulation by TLR2, and intracellular feedback loops [2,3,7].
Why is negative regulation of chemokine signaling important?
It prevents excessive inflammation, controls leukocyte trafficking, and is crucial for resolving immune responses [1,3].
What diseases are linked to defective negative regulation of chemokine signaling?
Chronic inflammatory diseases, cancer metastasis, and immunosenescence are associated with dysregulation of this process [1,3,6,8].
What experimental models are used to study GO:0070100?
Knockout mice, point mutant cell lines, overexpression models, and CRISPR screens are commonly used [2,3,7,8].
How can CRISPR help study negative regulation of chemokine signaling?
CRISPR knockout, point mutation, knock-in, and overexpression enable precise manipulation of genes involved in this pathway [2,3,7].
What is the role of ACKR2 in chemokine regulation?
ACKR2 acts as a decoy receptor that scavenges inflammatory chemokines, thereby reducing signaling.
How does TLR2 down-modulate chemokine receptors?
TLR2 activation leads to heterologous down-modulation of CCR1, CCR2, and CCR5 on monocytes, reducing chemokine responsiveness.
What methods measure negative regulation of chemokine signaling?
Transwell migration, calcium flux, cAMP assays, flow cytometry, and Western blotting are standard methods [1,2,4,7].
Conclusion
Negative regulation of chemokine-mediated signaling (GO:0070100) is a vital biological process that prevents excessive inflammation and maintains immune homeostasis. Key mechanisms include receptor desensitization, decoy receptors, and heterologous down-modulation. Dysregulation contributes to inflammatory diseases and cancer, making it an attractive therapeutic target. EDITGENE offers comprehensive CRISPR solutions to study this pathway and accelerate drug discovery.
References
- 1. Subramanian P et al.. 2016. Regulation of tissue infiltration by neutrophils: role of integrin α3β1 and other factors.. Curr Opin Hematol 23(1):36-43 PMID: 26554893
- 2. Brox R et al.. 2018. Molecular Mechanisms of Biased and Probe-Dependent Signaling at CXC-Motif Chemokine Receptor CXCR3 Induced by Negative Allosteric Modulators.. Mol Pharmacol 93(4):309-322 PMID: 29343553
- 3. O'Boyle G et al.. 2007. Chemokine-mediated inflammation: Identification of a possible regulatory role for CCR2.. Mol Immunol 44(8):1944-53 PMID: 17081610
- 4. Broxmeyer HE et al.. 2001. Chemokine regulation of hematopoiesis and the involvement of pertussis toxin-sensitive G alpha i proteins.. Ann N Y Acad Sci 938:117-27; discussion 127-8 PMID: 11458498
- 5. Stratman AN et al.. 2020. Chemokine mediated signalling within arteries promotes vascular smooth muscle cell recruitment.. Commun Biol 3(1):734 PMID: 33277595
- 6. Zhang Y et al.. 2024. Antibody and transcription landscape in peripheral blood mononuclear cells of elderly adults over 70 years of age with third dose of COVID-19 BBIBP-CorV and ZF2001 booster vaccine.. Immun Ageing 21(1):11 PMID: 38280989
- 7. Fox JM et al.. 2011. TLR2-dependent pathway of heterologous down-modulation for the CC chemokine receptors 1, 2, and 5 in human blood monocytes.. Blood 117(6):1851-60 PMID: 21148810
- 8. Laufer JM et al.. 2018. ZAP70 expression enhances chemokine-driven chronic lymphocytic leukemia cell migration and arrest by valency regulation of integrins.. FASEB J 32(9):4824-4835 PMID: 29589978
